Karyopharm Therapeutics Inc. (25K0)
XFRA 
Summary
Karyopharm Therapeutics Inc. (KPTI) Q1 2026 Earnings Call Transcript
Karyopharm Therapeutics Inc. (KPTI) Q1 2026 Earnings Call Transcript
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Beats Revenue Estimates
Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $1.45. This compares to a loss of $2.77 per share a year ago.
Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?
Karyopharm Therapeutics (KPTI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Karyopharm Therapeutics Inc. (25K0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Karyopharm Therapeutics Inc. ever had a stock split?
Karyopharm Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Richard A. Paulson CEO | XFRA Exchange | 48576U205 CUSIP |
| US Country | 228 Employees | - Last Dividend | 26 Feb 2025 Last Split | 6 Nov 2013 IPO Date |
Overview
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company based in Newton, Massachusetts, established in 2008. The company is focused on the discovery, development, and commercialization of novel treatments for cancer and other diseases, targeting the nuclear export process. Karyopharm's approach centers on inhibiting the nuclear export protein exportin 1 (XPO1), employing its proprietary Selective Inhibitor of Nuclear Export (SINE) compounds. Through strategic partnerships and licensing agreements, Karyopharm seeks to expand its therapeutic reach within the oncology sector and beyond.
Products and Services
- XPOVIO
XPOVIO is Karyopharm’s lead compound, utilized in various combinations for treating multiple myeloma and diffuse large B-cell lymphoma (DLBCL). It is currently approved for use in combination with bortezomib and dexamethasone for adults with multiple myeloma, in combination with dexamethasone for adults with relapsed or refractory multiple myeloma, and for adults with relapsed or refractory DLBCL. - Selinexor
This is another SINE compound developed by Karyopharm, with a focus on a range of hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL. Through licensing agreements, Selinexor is being advanced globally for various oncology applications. - ELTANEXOR
Karyopharm is developing ELTANEXOR for the treatment of Myelodysplastic Neoplasms. This compound represents the company's ongoing commitment to expanding its portfolio into new therapeutic areas within oncology. - Additional Compounds
Karyopharm is also working on several other compounds, including verdinexor, KPT-9274, and IL-12-based compounds, targeting a broad spectrum of diseases. These efforts underscore the company's diverse approach to drug development and its aim to address unmet medical needs across different patient populations.
